Clinical Trial

A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter Phase Ib/II clinical trial of LBL-024 in combination with other drugs for the treatment of patients with platinum-resistant ovarian cancer (OC), aiming to evaluate the efficacy and safety of LBL-024 in combination with other drugs in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC).
Protocol Amendment History 2 changes
notable Enrollment increased: 110 -> 180 participants 2026-08-14
minor Trial arms changed: 2 -> 4 2026-08-14
Trial Details
NCT Number NCT07042802
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Conditions Ovarian Cancer
Enrollment 180 participants
Start Date 2025-12-02
Primary Completion 2027-12-25 (estimated)
Study Completion 2028-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-13